441 results on '"Feng-Ming Kong"'
Search Results
402. SU-E-T-293: A Radiobiological Model Based Approach to Evaluate Brain Radiotherapy Fractionation Regimens
403. A phase II trial of mid-treatment FDG-PET adaptive, individualized radiation therapy plus concurrent chemotherapy in patients with non-small cell lung cancer (NSCLC)
404. Serum miRNA signature to identify a patient’s resistance to high-dose radiation therapy for unresectable non-small cell lung cancer
405. Total lesion glycolysis (TLG) at baseline FDG-PET/CT compared with maximum standard uptake value (SUVmax) to predict survival in non-small cell lung cancer (NSCLC)
406. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker
407. Transforming growth factor-beta receptors and mannose 6-phosphate/insulin-like growth factor-II receptor expression in human hepatocellular carcinoma
408. The association of plasma TGFβ1 during radiotherapy and genotypes of TGFβ1 pathway in patients with non-small cell lung cancer
409. Changes in plasma transforming growth factor β1 during radiotherapy: an independent predictor of radiation pneumonitis
410. Plasma Cytokine Profile during Radiotherapy may Predict Symptomatic Radiation-induced Lung Toxicity in Patients with Non–small-cell Lung Cancer
411. A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small-Cell Lung Cancer.
412. PATTERNS OF PRACTICE IN LIMITED-STAGE SMALL CELL LUNG CANCER (LS-SCLC) AMONG RADIATION ONCOLOGISTS
413. P3-201: Radiation dose is significantly associated with overall survival in patients with stage III non-small cell lung cancer treated with combined radiation and chemotherapy
414. PD5-1-4: Differences in pattern of practice in radiation therapy for patients with non-small cell lung cancer between physicians from the United States and Other Countries
415. Radiothérapie de conformation en trois dimensions des cancers bronchiques non à petites cellules stades IIIA–IIIB avec irradiation sélective des aires ganglionnaires: analyses des doses d'irradiation reçues par les aires ganglionnaires localisées en dehors du volume cible
416. TH-E-230A-06: Comparison of Correction and Model Based Dose Algorithms in Lung Cancer Retrospective Dose Recalculation and Treatment Outcome Evaluation
417. 69 PATTERNS OF LOCAL/REGIONAL FAILURE AFTER HIGH DOSE RADIATION IN PATIENTS WITH INOPERABLE/UNRESECTABLE NON-SMALL CELL LUNG CANCER
418. Identification of M6P/IGF2R as a tumor suppressor gene in lung cancer
419. 519 Hyperfractionated acelerated radiation therapy for non-small cell lung cancer: Clinical phase 111 trial
420. Bacterial cell wall polymers promote intestinal fibrosis through stimulation of myofibroblast activity
421. 26 Increased plasma transforming growth factor beta1 (TGFβ1) level in lung cancer patients may be due to the loss of mannose 6-phosphate/insulin like growth factor 2 receptor ()
422. 2155 Plasma transforming growth factor beta1 (TGFβ1): A monitor for persistence or recurrence of disease in patients with lung cancer
423. 2203 Changes in plasma transforming growth factor beta1 (TGFβ1) levels in prostate cancer patients during radiotherapy may help select patients for adjuvant hormonal treatment
424. 158 Physical and biological predictors of radiation-induced whole lung injury: Early results of a prospective study
425. ACR Appropriateness Criteria® Nonsurgical Treatment for Non-Small-Cell Lung Cancer: Good Performance Status/Definitive Intent.
426. Radiation produces differential changes in cytokine profiles in radiation lung fibrosis sensitive and resistant mice.
427. 1033 Elevated circulating transforming growth factor beta1 (TGFB1) levels decreased after radiotherapy in patients with lung cancer, cervical cancer and Hodgkin's disease: A possible tumor marker
428. 126 Changes in plasma TGFβ levels during thoracic irradiation: a potential tool for selecting patients for dose escalation
429. 18F-FDG PET Definition of Gross Tumor Volume for Radiotherapy of Non--Small Cell Lung Cancer: Is a Single Standardized Uptake Value Threshold Approach Appropriate?
430. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome
431. Single Nucleotide Polymorphisms in DNA Repair Genes May Be Associated with Survival in Patients with Non-small Cell Lung Cancer Treated with Definitive Radiotherapy
432. A PHASE II TRIAL OF MID-TREATMENT FDGPET ADAPTIVE, INDIVIDUALIZED RADIATION THERAPY PLUS CONCURRENT CHEMOTHERAPY IN PATIENTS WITH INOPERABLE NON-SMALL CELL LUNG CANCER (NSCLC)
433. Thymic malignancies
434. Thymomas and thymic carcinomas
435. SERUM MICRORNA AS A PREDICTIVE MARKER FOR RADIATION PNEUMONITIS IN PATIENTS WITH INOPERABLE/UNRESECTABLENON-SMALL CELL LUNG CANCER (NSCLC)
436. Using ROC Analysis to Determine the Optimal Lung Dosimetric Parameter as the Risk Factor of Survival for SBRT in NSCLC Patients
437. Association between genetic variations in transforming growth factor beta pathway and overall survival in patients with non-small cell lung cancer treated with definitive radiotherapy
438. PD5-1-5: Radiation-induced elevation in plasma TGF-beta1 during radiation therapy may be predictive of radiation-induced lung toxicity in patients with non-small cell lung cancer: A combined analysis from Beijing and Michigan
439. The Adjunctive Effect of Acupuncture for Advanced Cancer Patients in a Collaborative Model of Palliative Care: Study Protocol for a 3-Arm Randomized Trial
440. Protocol for the Examination of Specimens From Patients With Primary Non--Small Cell Carcinoma, Small Cell Carcinoma, or Carcinoid Tumor of the Lung.
441. Reply to Z. Liao et al and R. Rengan et al.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.